Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease

NCT07737249 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Interstitial Lung Diseases

Interventions

DRUG: golidocitinib plus corticosteroid
DRUG: non-JAK inhibitor immunosuppressant plus corticosteroid

Sponsor

Peking Union Medical College Hospital